Comparison · NCT04662060-3915a3e9
Acebilustat vs Placebo: Number of Participants That Developed Antibodies to SARS-CoV-2
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Acebilustat vs Placebo: Number of Participants That Developed Antibodies to SARS-CoV-2. Trial comparisons, record NCT04662060-3915a3e9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04662060-3915a3e9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.932 | 1 | wilson | |
| Risk in group 2 | 1 | 0.935 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0676 | 0.0653 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 1 | 1 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Acebilustat | Participants receive acebilustat 100 mg for 28 days. | 53 | 53 | OG001 |
| Group 2 | Placebo | Participants receive placebo for 28 days. | 55 | 55 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants That Developed Antibodies to SARS-CoV-2
- Description
- Time frame
- 28 days
- Population
- Participants with available antibody data are included in the analysis.
Source ClinicalTrials.gov
Trial
- Title
- COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol
- NCT number
- NCT04662060
- Phases
- PHASE2
- Conditions
- Covid19
- Interventions
- Acebilustat, Placebo
- Lead sponsor
- Stanford University
- Results first posted
- 2023-06-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04662060?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04662060-3915a3e9